The emerging chronic obstructive pulmonary disease epidemic: Clinical impact, economic burden, and opportunities for disease management

Disease Management and Health Outcomes

Volumn 16, Issue 5, 2008, Pages 275-284

  Carter, Rick ^a   Tiep, Brian L ^b,c,d   Tiep, Rebecca E ^c  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c Respiratory Disease Management Institute   (United States)

^d WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

Chronic obstructive pulmonary disease, general; Disease management programmes

Indexed keywords

AIR QUALITY; BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE SURVEILLANCE; ECONOMIC ASPECT; EPIDEMIC; EXERCISE; HIGH RISK POPULATION; HUMAN; INCIDENCE; NOTE; NUTRITIONAL DISORDER; OCCUPATIONAL EXPOSURE; SMOKING HABIT; SPIROMETRY;

EID: 57649214110     PISSN: 11738790     EISSN: None     Source Type: Journal    
DOI: 10.2165/0115677-200816050-00002     Document Type: Note

References (98)

1. Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007; 370 (9589): 741-50
2. Definitions, epidemiology, pathophysiology, diagnosis, and staging. Am J Respir Crit Care Med 1995; 152: S78-S83
3. Pauwels RA, Rabe KF. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet 2004; 364: 613-20
4. Heron MP, Smith BL. Deaths: leading causes for 2003. Centers for Disease Control and Prevention, National Center for Health Statistics [online]. Available from URL: http://www.cdc.gov/nchs/products/pubs/pubd/hestats/ leadingdeaths03/leadingdeaths03.htm#fig1 [Accessed 2008 Sep 26]
5. Mannino DM, Homa DM, Akinbami LJ, et al. Chronic obstructive pulmonary disease surveillance: United States, 1971-2000. MMWR CDC Surveill Summ 2002; 51 (SS06): 1-16 [online]. Available from URL: http://www.cdc.gov/mmwr/preview/ mmwrhtml/ss5106a1.htm#fig1 [Accessed 2008 Sep 26]
6. Romieu I, Trenga C. Diet and obstructive lung diseases. Epidemiol Rev 2001; 23 (2): 268-87
7. Fishman AF. Pulmonary diseases and disorders. New York: McGraw Hill, 1991
8. Carter R, Nicotra B, Sanfelippo P. Reversing pathophysiologic changes of chronic obstructive pulmonary disease with lung volume reduction surgery and exercise rehabilitation. Clin Pulm Med 1996; 3 (5): 237-48
9. Pauwels RA, Buist AS, Calverley PM, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Global Initative for Chronic Obstructive Pulmonary Disease (GOLD) workshop summary. Am J Respir Crit Care Med 2001; 163: 1256-76
10. Celli BR. Standards for the optimal management of COPD: a summary. Chest 1998; 113 (4 Suppl.): 283S-7S
11. Bestall JC, Paul EA, Garrod R, et al. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999; 54 (7): 581-6
12. Celli B, Snider GL, Heffner JE, et al. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1995; 152: S77-120
13. Siafakas NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD): the European Respiratory Society Task Force. Eur Respir J 2007; 8: 1398-420
14. Global Initiative for Chronic Obstructive Lung Disease. GOLD guidelines and resources [online]. Available from URL: http://www.goldcopd.com/ guidelinesresources.asp?l1=2&l2=0 [Accessed 2008 Oct 8]
15. Celli BR, Macnee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper [published erratum appears in Eur Respir J 2006; 27 (1): 242]. Eur Respir J 2004; 23 (6): 932-946 [online]. Available from URL: http://www.ers-education. org/pages.default.aspx?id=725 [Accessed 2008 Oct 8]
16. Brownson RC, Remington PL, Davis JR. Chronic disease epidemiology and control. 2nd ed. Washington, DC: American Public Health Association, 1998
17. McGinnis JM, Foege WH. Actual causes of death in the United States. JAMA 1993; 270: 2207-12
18. US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics, Division of Data Services. Ten leading causes of death, 2005: US and all 50 states, listed by age-adjusted death rates [online]. Available from URL: http://www.cdc.gov/nchs/ pressroom/data/state_mortality_rank_05.htm [Accessed 2008 Oct 8]
19. World Health Organization. Chronic diseases and their common risk factors: facing the facts #1. Geneva: World Health Organization, 2005
20. World Health Organization. Global strategy on diet, physical activity and health: chronic disease risk factors. Geneva: World Health Organization, 2007 [online]. Available from URL: http://www.who.int/gb/ebwha/pdf_files/WHA57/ A57_R17-en.pdf [Accessed 2008 Oct 8]
21. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020. Lancet 1997; 349: 1498-504
22. Halbert RJ, Isonaka S, George D, et al. Interpretating COPD prevalence estimates: what is the true burden of disease? Chest 2003; 123: 1684-92
23. Carter R, Nicotra B. The effect of exercise training and rehabilitation on functional status in patients with chronic obstructive pulmonary disease (COPD). Int J Rehabil Health 1996; 2 (3): 143-67
24. Mannino DM, Homa DM, Akinbami LJ, et al. Chronic obstructive pulmonary disease surveillance: United States 1971-2000. MMWR 2002; 51: 1-16
25. Tiep BL, Barnett MC. Disease management for chronic obstructive pulmonary disease: a clinical strategy. Dis Manage Health Outcomes 2008; 16 (5): 305-13
26. Manual of the international statistical classification of diseases, injuries, and causes of death, 9th revision. Geneva: World Health Organization, 1977
27. International Statistical Classification of diseases and related health problems. 10th revision. Geneva: World Health Organization, 1992
28. Centers for Medicare and Medicaid Services. National health expenditure data [online]. Available from URL: http://www.cms.hhs.gov/ nationalhealthexpenddata/ [Accessed 2008 Oct 8]
29. Mannino DM, Buist AS, Petty TL, et al. Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow-up study. Thorax 2003; 58 (5): 388-93
30. Petty TL. Scope of the COPD problem in North America: early studies of prevalence and NHANES III data. Basis for early identification and intervention. Chest 2000; 117: 326S-31S
31. Stang P, Lydick E, Silberman C, et al. The prevalence of COPD: results of the IBERPOC multicenter epidemiology study. Chest 2000; 117: 354S-9S
32. Sobradillo-Pena V, Miravitlles M, Gabriel R, et al. Geographic variations in prevalence and underdiagnosis of COPD: results of the IBERPOC multicenter study. Chest 2000; 118: 981-9
33. Murtagh E, Heaney L, Gingles J, et al. Prevalence of obstructive lung disease in a general population sample: the NICECOPD study. Eur J Epidemiol 2005; 20 (5): 443-53
34. Buist AS, Vollmer WM, Sullivan SD, et al. The Burden of Obstructive Lung Disease initiative (BOLD): rationale and design. COPD 2005; 2 (2): 277-83
35. Gulsvik A. The global burden and impact of chronic obstructive pulmonary disease worldwide. Monaldi Arch Chest Dis 2001; 56 (3): 261-4
36. Mannino DM, Brown C, Giovino GA. Obstructive lung disease deaths in the United States from 1979 through 1993. Am J Respir Crit Care Med 1997; 156: 814-8
37. Zielinski J, Macnee W, Wedzicha J, et al. Cause of death in patients with COPD and respiratory failure. Monaldi Arch Chest Dis 1997; 52: 43-7
38. Hansell AL, Walk JA, Soriano JB. What do chronic obstructive pulmonary disease patients die from? Eur Respir J 2003; 22: 809-14
39. Meyer PA, Mannino DM, Redd SC, et al. Characteristics of adults dying with COPD. Chest 2002; 122: 2003-8
40. Fletcher CM. The natural history of chronic bronchitis and emphysema. Oxford (UK): Oxford University Press, 1976
41. Menotti A, Blackburn H, Seccareccia F, et al. The relationship of chronic diseases to all-cause mortality risk: the Seven Countries study. Ann Med 1997; 29: 135-41
42. Vestbo J, Prescott E, Lange P, et al. Vital prognosis after hospitalization for COPD. Respir Med 1998; 92: 772-6
43. Barter C, Campbell AH. Relationship of constitutional factors and smoking to decrease the 1-second forced expiratory volume. Am Rev Respir Dis 1976; 113: 305-14
44. Hansen EF, Phanareth K, Laursen LC, et al. Reversible and irreversible airflow obstruction as predictor of overall mortality in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159: 1276-1
45. France AJ, Prescott E, Biernacki W. Does right ventricular function predict survival in patients with chronic obstructive pulmonary disease? Thorax 1988; 43 (8): 621-6
46. Incalzi RA, Fuso L, De Rosa M, et al. Co-morbidity contributions to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J 1997; 10: 2794-800
47. Connors AF, Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 154: 959-67
48. Marton JP, Boulanger L, Friedman M, et al. Assessing the costs of chronic obstructive pulmonary disease: the state medicaid perspective. Respir Med 2006; 100 (6): 996-1005
49. Mapel DW. Estimating the cost of COPD: a matter of perspective. COPD 2006; 3 (4): 177-8
50. Tinkelman D, Nordyke RJ, Isonaka S, et al. The impact of chronic obstructive pulmonary disease on long-term disability costs. J Manag Care Pharm 2005; 11 (1): 25-32
51. Nowak D, Berger K, Lippert B, et al. Epidemiology and health economics of COPD across Europe: a critical analysis. Treat Respir Med 2005; 4 (6): 381-95
52. Fournier M, Tonnel AB, Housset B, et al. Economic burden of COPD: the SCOPE study [in French]. Rev Mal Respir 2005; 22 (2 Pt 1): 247-55
53. Borg S, Ericsson A, Wedzicha J, et al. A computer simulation model of the natural history and economic impact of chronic obstructive pulmonary disease. Value Health 2004; 7 (2): 153-67
54. Wouters EF. Economic analysis of the confronting COPD survey: an overview of results. Respir Med 2003; 97 Suppl. C: S3-14
55. National Institutes of Health. NIH launches new campaign aimed at increasing awareness, early diagnosis and treatment for COPD: communications effort augments NHLBI's investment in COPD research [press release]. NIH News 2007 [online]. Available from URL: http://www.nih.gov/news/pr/jan2007/nhlbi-18a. htm [Accessed 2008 Sep 29]
56. Chapman KR, Bourbeau J, Rance L. The burden of COPD in Canada: results from the Confronting COPD survey. Respir Med 2003; 97 Suppl. C: S23-31
57. Izquierdo JL. The burden of COPD in Spain: results from the Confronting COPD survey. Respir Med 2003; 97 Suppl. C: S61-9
58. Britton M. The burden of COPD in the UK: results from the Confronting COPD survey. Respir Med 2003; 97 Suppl. C: S71-9
59. Hoogendoorn M, Rutten-van Molken MP, Hoogenveen RT, et al. A dynamic population model of disease progression in COPD. Eur Respir J 2005; 26 (2): 223-33
60. Briggs AH, Lozano-Ortega G, Spencer S, et al. Estimating the cost-effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data. Value Health 2006; 9 (4): 227-35
61. Nishimura S, Zaher C. Cost impact of COPD in Japan: opportunities and challenges? Respirology 2004; 9 (4): 466-73
62. Detournay B, Pribil C, Fournier M, et al. The SCOPE study: health-care consumption related to patients with chronic obstructive pulmonary disease in France. Value Health 2004; 7 (2): 168-74
63. Wouters EF. The burden of COPD in the Netherlands: results from the Confronting COPD survey. Respir Med 2003; 97 Suppl. C: S51-9
64. Dal NR, Rossi A, Cerveri I. The burden of COPD in Italy: results from the Confronting COPD survey. Respir Med 2003; 97 Suppl. C: S43-50
65. Sandford AJ, Weir TD, Pare PD. Genetic risk factors for chronic obstructive pulmonary disease. Eur J Appl Physiol 1997; 10: 1380-91
66. Alpha-1 Committee. Alpha-1 disease management and prevention program. Gainsville (FL): Alpha Net Inc., 2004
67. McElvaney NG, Stroller JK, Buist AS, et al. Baseline characteristics of enrollees in the National Heart, Lung, and Blood Institute registry of alpha-1 antitrypsin deficiency: Alpha 1-Antitrypsin Deficiency Registry Study Group. Chest 1997; 111 (2): 394-403
68. O'Connor GT, Sparrow D, Weiss ST. A prospective longitudinal study of methacholine airway responsiveness as a predictor of pulmonary-function decline: the Normative Aging Study. Am J Respir Crit Care Med 1995; 152: 97-2
69. Tashkin DP, Detels R, Simmons M, et al. The UCLA population studies of chronic obstructive respiratory disease: XI. Impact of air pollution and smoking on annual change in forced expiratory volume in one second. Am J Respir Crit Care Med 2007; 149: 1209-17
70. Huber GL, Mahajan VK. Successful smoking cessation. Dis Manage Health Outcomes 2008; 16 (5): 335-43
71. Gold DR, Wang X, Wypij D, et al. Effects of cigarette smoking on the pulmonary function in adolescent boys and girls. N Engl J Med 1996; 335: 931-7
72. Huber GL, Mahajan VK, Rubin AH. Theoretical and experimentally quantifiable determinants of tobacco smoking behavior for the development of successful smoking cessation strategies. Cancer Detect Prev 1990; 14: 505-14
73. Holland WW, Reid DD. The urban factor in chronic bronchitis. Lancet 1965; I: 445-6
74. 1 with time: indicators for effects of smoking and air pollution. Bull Eur Physiopathol Respir 1981; 17: 775-92
75. Detels R, Tashkin DP, Sayre JW, et al. The UCLA population studies of COPD: X. A cohort study of changes in respiratory function associated with chronic exposure to SOx, NOx, and hydrocarbons. Am J Public Health 1991; 81: 350-9
76. Ackermann-Liebrich U, Leuenberger P, Schwartz J, et al. SAPALDIA team. Lung function and long term exposure to air pollutants in Switzerland. Am J Respir Crit Care Med 1997; 155: 122-9
77. 2 in eight areas of Switzerland. Epidemiology 1998; 9: 405-11
78. Peters JM, Avol E, Gauderman J, et al. A study of twelve southern California communities with different levels and types of air pollution. Am J Respir Crit Care Med 1999; 159: 768-75
79. Raizenne M, Neas LM, Damokosk AI, et al. Health effects of acid aerosols on North American children: pulmonary function. Environ Health Perspect 1996; 104: 506-14
80. Stern BR, Raizenne ME, Burnett RT, et al. Air pollution and childhood respiratory health: exposure to sulfate and ozone in 10 Canadian rural communities. Environ Res 1994; 66: 125-42
81. Fairbairn AS, Reid DD. Air pollution and other local factors in respiratory disease. Br J Prev Soc Med 1958; 12: 94-103
82. Lambert PM, Reid DD. Smoking, air pollution and bronchitis in Britain. Lancet 1970; 1: 853-7
83. Ferris BG, Higgins TT, Higgins MW, et al. Chronic nonspecific respiratory disease. Am Rev Respir Dis 1971; 104: 232-44
84. Love G, Shu Ping Lan, Smy C, et al. The incidence and severity of acute respiratory illness in families exposed to different levels of air pollution, New York Metropolitan Area. Arch Environ Health 1981; 36: 66-74
85. Burrows B, Kellogg ALL, Buskey S. Relationship of symptoms of chronic bronchitis and emphysema to matter and air pollution. Arch Environ Health 1968; 16: 406-13
86. Stachan DP, Cox BD, Erzinclioglu SW, et al. Ventilatory function and winter fresh fruit consumption in a random sample of British adults. Thorax 1991; 46: 624-9
87. Schwartz J, Weiss ST. Dietary factors and their relationship to respiratory symptoms. Am J Epidemiol 1990; 132: 67-76
88. Shahar E, Folsom AR, Melnick SL, et al. Dietary n-3 polyunsaturated fatty acids and smoking-related chronic obstructive pulmonary disease: Athrosclerosis Risk in Communities Study Investigators. N Engl J Med 1994; 331: 228-33
89. Swartz J. Role of polyunsaturated fatty acids in lung disease. Am J Clin Nutr 2000; 71 Suppl. 1: 393S-6S
90. Prescott E, Lange P, Vestbo J. Socioeconomic status, lung function and admission to hospital for COPD. Eur Respir J 1999; 13: 1109-14
91. Demissie K. Socioeconomic status and lung function among primary children in Canada. Am J Respir Crit Care Med 1986; 153: 719-23
92. Krzyzanowski M, Jedrychowski W, Wysocki M. Factors associated with the change in ventilatory function and the development of chronic obstructive pulmonary disease in a 13-year follow-up of the Cracow study. Am Rev Respir Dis 1986; 134: 1011-9
93. Bakke PS, Hanoa R, Gulsvik A. Educational level and obstructive lung disease given smoking habits and occupational airborne exposure: a Norwegian community study. Am J Epidemiol 1995; 141: 1080-8
94. Koster A, Bosma H, Kempen GI, et al. Socioeconomic inequalities in mobility decline in chronic disease groups (asthma/COPD, heart disease, diabetes mellitus, low back pain): only a minor role for disease severity and comorbidity. J Epidemiol Community Health 2004; 58 (10): 862-9
95. Britten N, Daves JMC, Colley JRT. Early respiratory experience and subsequent cough and peak expiratory flow rate in 36 year old men and women. BMJ 1987; 294: 1317-20
96. Britton J, Pavord I, Richards K, et al. Dietary magnesium, lung function, wheezing, and airway hyperreactivity in a random adult population sample. Lancet 1994; 344: 357-62
97. Lantz PM, House JS, Lepkowski JM, et al. Socioeconomic factors, health behaviors, and mortality. JAMA 1998; 279 (21): 1703-8
98. Petty TL. Chronic obstructive pulmonary disease: the challenge and the solution. Dis Manage Health Outcomes 2008; 16 (5): 273-74